Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with endometrial cancer (cancer of the lining of the uterus) that has come back or spread, confirmed by a laboratory test on a tissue sample
• People whose cancer has a specific molecular feature — either "dMMR" or "MSI-H" — confirmed by the trial's central laboratory before treatment begins
• People with advanced endometrial cancer (Stage III or IV) or a first recurrence of the disease that is unlikely to be cured by radiation or surgery alone, and who have at least one measurable area of cancer that can be tracked
• People who fall into at least one of these groups: (a) have Stage III or IV disease and have not yet had any systemic (whole-body) cancer treatment for endometrial cancer; (b) have a first recurrence and have not yet had any systemic cancer treatment for endometrial cancer; or (c) had treatment before or after surgery and the cancer came back or worsened 6 or more months after finishing that treatment (first recurrence only)
• People who have a stored tumour tissue sample available for testing, or who are able to provide a new tissue sample before treatment starts
• People who are not pregnant or breastfeeding, and who agree to use a highly effective form of contraception during the study if there is a possibility of becoming pregnant
• People whose general health and ability to carry out daily activities meets a standard rating of 0 or 1 on a recognised medical scale (meaning fully active or restricted in strenuous activity only)
• People whose blood, kidney, liver, and clotting functions are within acceptable ranges as assessed by laboratory tests

Who may not be able to join:

• People who currently have another cancer, or who have had a different type of invasive cancer (other than endometrial cancer) within the past 3 years or received active treatment for another cancer in the past 3 years — though a history of certain non-serious skin cancers is generally permitted
• People who have a history of a lung condition called interstitial lung disease or inflammation of the lungs (pneumonitis)
• People who have liver scarring (cirrhosis) or current unstable liver or bile duct disease
• People who have cancer that has spread to the brain or spinal fluid in a way that is not controlled, or both
• People who have been diagnosed with a condition that weakens the immune system (immunodeficiency)
• People who have previously been treated with certain types of immunotherapy drugs that target specific proteins involved in immune response (known as anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 agents)
• People who have not yet sufficiently recovered from side effects of previous treatments
• People who have received any cancer treatment (including chemotherapy, targeted therapy, hormone therapy, radiation, or immunotherapy) within 21 days before the planned start of the trial treatment
• People who have received a live vaccine within 30 days before the planned start of trial treatment — noting that authorised COVID-19 vaccines are not considered a reason for exclusion
• People who test positive for Hepatitis B surface antigen or active Hepatitis C virus at screening or within 3 months before the planned start of treatment
• People with a known HIV infection
• People who are currently taking part in another clinical trial or have received an experimental treatment or device within 4 weeks before the planned start of this trial
• People for whom the chemotherapy drugs carboplatin or paclitaxel are medically unsuitable

Important: Always verify eligibility with the trial site directly before applying.